Augustina Isioma Ikusemoro: Quality Indicators for Red Blood Cells in Transfusion Medicine
Augustina Isioma Ikusemoro, Hematology and Transfusion Medicine Specialist at Sharjah Blood Transfusion and Research Center, shared a post on LinkedIn:
“Quality Indicators for Red Blood Cells in Transfusion Medicine
Ensuring the quality of Red Blood Cell (RBC) components is critical for safe and effective transfusion therapy.
Both Packed RBCs and Apheresis RBCs are monitored through strict quality indicators aligned with standards from the AABB.
Key parameters include:
Hemoglobin Content
Ensures adequate oxygen-carrying capacity.
- Packed RBCs: ≥50 g/unit
- Apheresis RBCs: ≥80 g/unit
Hematocrit
Reflects red cell concentration and transfusion efficiency.
- Typical range: 50–70%
Hemolysis at Expiry
Indicator of membrane integrity during storage.
Acceptable limit: ≤1%
Unit Volume Consistency
Standard volumes under Unit Volume Consistency:
- Packed RBCs: 250–350 mL
- Apheresis RBCs: 300–400mL
Ensures standardized dosing and predictable clinical outcomes.
Residual Leukocyte Count (Leukoreduction)
- Target: <5 × 10⁶ leukocytes/unit
Reduces febrile reactions, alloimmunization, and CMV transmission risk.
Sterility
All RBC units must remain free of microbial contamination.
Maintaining these quality indicators strengthens blood safety, regulatory compliance, and patient outcomes in modern transfusion medicine.
Ultimately, every RBC unit transfused represents a carefully controlled biological therapy designed to deliver life-saving oxygen to patients who need it most.”
Other posts featuring Augustina Isioma Ikusemoro on Hemostasis Today.
-
Oct 6, 2026, 22:43Alessandra Bosch: Pediatric GTH Opens with Regional Experts Convening on Pediatric Hemostasis and Thrombosis
-
Oct 6, 2026, 22:39Managing Thrombotic Risk in Pregnancy – How the Lab May Help – Sysmex Europe
-
Oct 6, 2026, 22:33Ahmet Davut Aksu: A Multi-Objective Approach to Enhance Fibrinolysis, Selectivity, and Inhibition Resistance
-
Oct 6, 2026, 22:29Muhammad Abubakar: New Study on Iron Biology to Be Presented at ASH 2026 and Published in Blood
-
Oct 6, 2026, 22:24David McIntosh: Calling On Decision-Makers to Prioritize Donors and Clinical Access During IPAW 2026
-
Oct 6, 2026, 22:21Zoltan Nagy: With All Eyes on Optogenetics Today, What Can It Do in Megakaryocytes and Platelets?
-
Oct 6, 2026, 22:13Khalid A. Fakhro: Sidra Medicine Hosts RAPID 2026 Advancing Diagnostics and Treatments for Inborn Errors of Immunity
-
Oct 6, 2026, 22:04Denis Oduor: Preparedness for Postpartum Haemorrhage Must Include Preparedness for Blood
-
Oct 6, 2026, 21:57Farhad Moradpour: Health Equity and Public Health – What Drives Anemia Disparities in Ethnic Minority Populations?